Dianthus Therapeutics Income Statement (2017-2025) | DNTH

1Y3Y5Y7Y10YAll
Download Data
Income Statement Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & Cost
Revenue 1.17M1.18M0.50M1.00M0.92M0.43M0.87M1.86M2.17M1.33M1.16M0.19M0.40M
Operating Items
Amortization - Intangibles 0.52M0.42M2.34M1.90M1.10M2.31M
Research & Development 3.32M5.21M5.55M7.85M9.68M11.42M12.39M10.54M13.43M16.52M18.71M13.96M12.61M11.79M7.22M9.83M5.85M10.25M7.96M8.78M13.08M18.07M25.54M26.41M27.00M26.25M32.49M
Selling, General & Administrative 1.49M1.80M2.62M3.46M4.34M5.28M5.54M5.81M5.91M6.12M5.92M7.28M7.40M6.59M2.21M2.04M2.31M2.49M8.72M4.63M5.64M6.00M6.53M6.83M7.34M8.87M8.20M
Operating Expenses 4.81M7.01M8.17M11.31M14.03M16.70M17.93M16.35M19.34M22.64M24.64M21.24M20.01M18.38M9.43M11.87M8.16M12.74M16.68M13.41M18.72M24.07M32.07M33.24M34.34M35.12M40.68M
Operating Income -15.73M-7.01M-8.17M-11.31M-14.03M-16.70M-17.93M-16.35M-19.34M-22.64M-24.64M-21.24M-20.01M-18.38M-8.25M-10.69M-7.68M-11.78M-15.76M-12.96M-17.84M-22.20M-29.90M-31.92M-33.18M-34.93M-40.29M
EBIT -15.73M-7.01M-8.17M-11.31M-14.03M-16.70M-17.93M-16.35M-19.34M-22.64M-24.64M-21.24M-20.01M-18.38M-8.25M-10.69M-7.68M-11.78M-15.76M-12.96M-17.84M-22.20M-29.90M-31.92M-33.18M-34.93M-40.29M
Non-operating items
Interest & Investment Income 0.10M0.13M0.14M0.36M0.69M1.25M1.52M1.63M1.65M1.40M1.23M0.93M0.70M0.42M0.64M0.61M0.69M1.03M2.44M4.22M4.71M4.45M3.99M3.79M3.40M3.66M
Other Non Operating Income 0.06M-0.02M-0.01M-0.03M-0.02M-0.03M-0.11M-0.08M-0.05M-0.38M-0.10M-0.11M-0.36M
Non Operating Income 0.47M0.58M0.59M0.64M1.00M2.39M4.10M4.60M4.73M3.48M3.67M3.30M3.52M
Net income details
EBT -15.73M-6.91M-8.04M-11.16M-13.66M-16.02M-16.68M-14.83M-17.71M-20.99M-23.24M-20.01M-19.08M-17.68M-7.84M-10.05M-7.08M-11.09M-14.73M-10.51M-13.62M-17.50M-25.45M-27.93M-29.39M-31.52M-36.63M
Profit After Tax -15.73M-6.91M-8.04M-11.16M-13.66M-16.02M-16.68M-14.83M-17.71M-20.99M-23.24M-20.01M-19.08M-17.68M-7.78M-10.10M-7.10M-11.14M-14.76M-10.60M-13.75M-17.61M-25.17M-28.47M-29.51M-31.63M-36.77M
Income from Continuing Operations -15.73M-6.91M-8.04M-11.16M-13.66M-16.02M-16.68M-14.83M-17.71M-20.99M-23.24M-20.01M-19.08M-17.68M-7.84M-10.05M-7.08M-11.09M-14.73M-10.51M-13.62M-17.50M-25.45M-27.93M-29.39M-31.52M-36.63M
Consolidated Net Income -15.73M-6.91M-8.04M-11.16M-13.66M-16.02M-16.68M-14.83M-17.71M-20.99M-23.24M-20.01M-19.08M-17.68M-7.84M-10.05M-7.08M-11.09M-14.73M-10.51M-13.62M-17.50M-25.45M-27.93M-29.39M-31.52M-36.63M
Income towards Parent Company -15.73M-6.91M-8.04M-11.16M-13.66M-16.02M-16.68M-14.83M-17.71M-20.99M-23.24M-20.01M-19.08M-17.68M-7.84M-10.05M-7.08M-11.09M-14.73M-10.51M-13.62M-17.50M-25.45M-27.93M-29.39M-31.52M-36.63M
Preferred Dividend Payments 0.23M0.01M
Net Income towards Common Stockholders -15.39M-6.92M-8.04M-11.16M-13.75M-16.02M-16.68M-14.83M-17.71M-20.99M-23.24M-20.01M-19.08M-17.68M-7.84M-10.05M-7.08M-11.09M-14.73M-10.51M-13.62M-17.50M-25.45M-27.93M-29.39M-31.52M-36.63M
Additional items
EPS (Basic) -8.90-3.44-3.59-4.53-3.13-0.49-0.50-0.44-0.48-0.54-0.59-0.51-0.48-0.37-8.90-11.57-8.10-12.73-3.788.95-0.54-0.51-0.74-0.82-0.82-0.88-0.97
EPS (Weighted Average and Diluted) -8.90-11.57-8.10-12.73-3.788.95-0.54-0.51-0.74-0.82-0.82-0.88-0.97
Shares Outstanding (Weighted Average) 2.15M2.15M2.15M2.06M2.07M2.09M2.10M2.42M2.44M2.46M2.47M3.02M3.67M3.67M3.68M3.78M3.79M3.79M3.79M14.82M29.35M29.35M29.35M29.60M32.13M32.16M32.19M
Shares Outstanding (Diluted Average) 58.80M58.82M0.87M0.87M0.87M0.87M3.91M5.15M25.67M34.23M34.24M33.31M35.79M35.82M37.79M
EBITDA -4.81M-6.91M-8.04M-11.16M-13.66M-16.02M-16.69M-14.79M-17.61M-21.05M-23.31M-19.66M-19.29M-17.79M-7.93M-10.13M-6.99M-11.10M-14.75M-10.51M-13.82M-17.62M-24.46M-29.02M-29.35M-31.80M-36.70M